SPOTLIGHT:
The HIV Research for Prevention conference showcased advances with the potential to further decrease the rate of new infections.
GLOBAL NEWS
Gerald Voss, former head of GlaxoSmithKline (GSK) Vaccine’s HIV Vaccine program and vice president of the Enterprise’s Board of Directors, is now interim director of the Global HIV Vaccine Enterprise Secretariat, replacing longtime AIDS vaccine advocate William Snow, who has stepped down.